Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine

Memarnejadian, Arash; Roohvand, Farzin

doi:10.1016/j.cellimm.2009.11.005

Cited by 28 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD8+ T cells could be eliminated against NS3/4A expressing hepatocytes and tumor cells in mouse model. No side effect was observed and two patients had viral load reductions of up to 1.2 and 2.4 log10 and the development of HCV-specific T cell reported (Ma et al, 2002;O'Hagan et al, 2004;Park et al, 2008;Memarnejadian and Roohvand, 2010).…”

Section: Dna Vaccinesmentioning

confidence: 93%

“…Several methods were developed to improve naked DNA delivery such as using a gene gun for DNA vaccination, electroporation with electrical impulses which creates pores in living cells and puts DNA through the cell membrane (Desjardins et al, 2009). The first DNA vaccine evaluated in Cuba in Phase I trial, which is (CICGB-230) combining plasmid expressing HCV structural antigens (core/E1/E2) with recombinant core protein (Co.120) (Memarnejadian and Roohvand, 2010;Huret et al, 2012). Another HCV DNA-based vaccine is a T cell vaccine based on HCV non-structural 3/4A which expressed under the control of the Cytomegalovirus immediate early promoter (ChronVac-C has recently been developed by TripepAB Sweden) used electroporation to inject plasmid expressing HCV antigens NS3/4a.…”

Section: Dna Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development

Keyvani

Fazlalipour²,

Monavari³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Dna Vaccinesmentioning

confidence: 93%

Section: Dna Vaccinesmentioning

confidence: 99%

Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development

Keyvani

Fazlalipour²,

Monavari³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The human embryonic kidney (HEK 293T) and MT-2 cell lines were obtained from the National Cell Bank of Iran. Single-cell suspension of mouse splenocytes was prepared in a cell homogenizer (Memarnejadian and Roohvand, 2010). Cells were cultured in either DMEM (293T) or RPMI 1640 (MT-2 and spleenocytes) media (Chemicon), supplemented with 15% FBS (Gibco), L-glutamine (2 mmol/l), penicillin G (100 U/ml), streptomycin (100 mg/ml), HEPES (25 mmol/l), and maintained in 5% CO 2 and 37ºC.…”

Section: Methodsmentioning

confidence: 99%

Development of single-cycle replicable human immunodeficiency virus 1 mutants

Zabihollahi¹,

Sadat²,

Vahabpour³

et al. 2011

View full text Add to dashboard Cite

Summary. -Non-infectious but antigenic human immunodeficiency virus 1 (HIV-1) particles are essential tool for the research on many topics associated with this virus. Here we report the construction of plasmid containing the HIV-1 genome mutated in the pol gene, which was co-transfected with plasmids expressing the pol gene products reverse transcriptase (RT) and integrase (IN), and the glycoprotein G of vesicular stomatitis virus (VSV-G). The virions produced in HEK 293 T cells were antigenic, but able to replicate only for one cycle, e.g. first generation single-cycle replicable (SCR) virions. The presence of VSV-G in the envelope of these virions had to ensure a wider spectrum of susceptible cell types for the replication of SCR. Replication of the first generation SCR virions in HEK 293T, MT-2, and mouse spleen cells was examined by p24-capture ELISA, syncytium formation assay, and electron microscopy (EM). HEK 293T and MT-2 cell lines showed a similar replication capacity, while primary cultures of mouse spleen cells were much less effective. The infection of MT-2 cells with the first generation of SCR virions yielded the second generation SCR virions, which were noninfectious. Summing up, the HIV-1 SCR virions represent the useful tool for HIV-1 research facilitating a better biological safety. Moreover, considering their antigenic composition and limited replication, SCR virions may be a promising candidate for the vaccine studies.Keywords: human immunodeficiency virus 1; mutants; single-cycle replicable virions; AIDS vaccine * Corresponding author. Email: azadmanesh@pasteur.ac.ir; phone +9821-66969291.# These authors contributed equally to this paper. Abbreviations: EM = electron microscopy; HIV-1 = human immunodeficiency virus 1; IN = integrase; p.i. = post infection; RT = reverse transcriptase; SCR = single-cycle replicable; SIN = selfinactivating; SIV = simian immunodeficiency virus; VSV-G = vesicular stomatitis virus-glycoprotein G

show abstract

“…In a mouse model, HBV precore protein enhanced HCV-specific CTL responses induced by the genetic immunization of DNA encoding truncated HCV core proteins [68]. In another model, HBs antigen enhanced the induction of HCV-specific CTLs by DNA vaccine harboring HCV CTL epitopes [69]. …”

Section: Immunotherapy For Hepatitis Cmentioning

confidence: 99%

Immune Response of Cytotoxic T Lymphocytes and Possibility of Vaccine Development for Hepatitis C Virus Infection

Hiroishi

Eguchi

Ishii

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Immune responses of cytotoxic T lymphocytes (CTLs) are implicated in viral eradication and the pathogenesis of hepatitis C. Weak CTL response against hepatitis C virus (HCV) may lead to a persistent infection. HCV infection impairs the function of HCV-specific CTLs; HCV proteins are thought to actively suppress host immune responses, including CTLs. Induction of a strong HCV-specific CTL response in HCV-infected patients can facilitate complete HCV clearance. Thus, the development of a vaccine that can induce potent CTL response against HCV is strongly expected. We investigated HCV-specific CTL responses by enzyme-linked immuno-spot assay and/or synthetic peptides and identified over 40 novel CTL epitopes in the HCV protein. Our findings may contribute to the development of the HCV vaccine. In this paper, we describe the CTL responses in HCV infection and the attempts at vaccine development based on recent scientific articles.

show abstract

Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine

Abstract: To cite this version:Arash Memarnejadian, Farzin Roohvand. HBsAg conjoined with DNA-prime/peptide-boost immunization regimen seems a strategy to enhance the epitope-specific immune responses towards poly-CTL-epitopic vaccines.

Cited by 28 publications

References 35 publications

Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development

Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development

Development of single-cycle replicable human immunodeficiency virus 1 mutants

Immune Response of Cytotoxic T Lymphocytes and Possibility of Vaccine Development for Hepatitis C Virus Infection

Contact Info

Product

Resources

About